Kazia Therapeutics Ltd has experienced a significant price increase of 35.74%, reaching a 20-day high. This movement appears to be driven by technical factors rather than any specific news event.
The broader market context shows major benchmarks trading sideways with mixed signals, indicating a lack of clear directional trends. Despite this, KZIA.O has managed to stand out with its impressive gains.
Investors may be reacting to the stock's recent performance, as reaching a 20-day high often attracts attention and can lead to further buying momentum. Technical analysis suggests that such movements can create a positive feedback loop, encouraging more investors to enter the market.
Overall, while the market remains uncertain, Kazia Therapeutics Ltd's technical achievements have positioned it favorably in the current trading environment.
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
H.C. Wainwright
Buy
maintain
$13 -> $18
2025-12-12
Reason
H.C. Wainwright
Price Target
$13 -> $18
AI Analysis
2025-12-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Kazia Therapeutics to $18 from $13 and keeps a Buy rating on the shares. The company presented "encourating" results from its Phase 1 study of paxalisib for the treatment of triple-negative breast cancer, the analyst tells investors in a research note.
H.C. Wainwright
Sean Lee
Buy
upgrade
$2 -> $13
2025-07-10
Reason
H.C. Wainwright
Sean Lee
Price Target
$2 -> $13
2025-07-10
upgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee raised the firm's price target on Kazia Therapeutics to $13 from $2 and keeps a Buy rating on the shares following the adjusted ratio of U.S. shares to 500:1 from 100:1.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KZIA
Unlock Now
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$3
2025-02-06
Reason
Maxim Group
Jason McCarthy
Price Target
$3
2025-02-06
Initiates
Strong Buy
Reason
Maxim initiated coverage of Kazia Therapeutics with a Buy rating and $3 price target. The company's lead asset is paxalisib, a potent, oral, brain-penetrant small molecule inhibitor of PI3K and mTOR being developed as an adjuvant therapy to treat newly diagnosed unmethylated glioblastoma - GBM - multiforme, the analyst tells investors in a research note. Paxalisib has shown numerical overall survival benefits in two studies involving unmethylated GBM patients, and while the drug did not progress to the second stage after being evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment platform trial, it demonstrated consistent overall survival benefits with a prior Phase 2 study, Maxim notes, adding that Kazia is on pace to initiate a Phase 3 trial for paxalisib in the second half of this year.
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
